- Home
- MOGU vs XCUR Comparison
MOGU vs XCUR Comparison
Compare MOGU & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOGU | XCUR |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 13.7M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MOGU | XCUR |
|---|---|---|
| Price | $2.01 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5K | ★ 239.4K |
| Earning Date | 01-29-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $1.43 |
| 52 Week High | $8.10 | $9.48 |
Technical Indicators
Market Signals| Indicator | MOGU | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 34.94 |
| Support Level | $1.85 | $1.43 |
| Resistance Level | $2.11 | $2.02 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 76.09 | 22.31 |
Price Performance
Historical ComparisonAbout MOGU MOGU Inc.
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.